跳至主要内容
临床试验/NCT07221812
NCT07221812尚未招募不适用

Continuous Glucose Monitors (CGMs) and Readmission Rates

University of Maryland, Baltimore2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2025年11月18日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
120
试验地点
2
主要终点
Change in glycemic control

研究概览

简要总结

Among the diffident groups of patients, those with chronic and severe medical conditions are more likely to be readmitted to the hospital. It is not surprising therefore that patients with diabetes have high readmission rates. Patients with diabetes have 40% higher re-hospitalization rates compared with those patients without diabetes, with 30-day readmission rates reported to range between 14% and 26%. It should be noted that almost 30% of the patients with diabetes are experiencing two or more hospital admissions per year, accounting for more than 50% of total hospitalizations and hospital health care costs. This research application will evaluate whether the initiation of Continuous Glucose Monitor (CGM) devices at the time of hospital discharge will lead to better glucose control and health outcomes compared to the use of "finger sticks" Point of Care (POC) following hospital discharge among patients with diabetes. This study will be a two arm (Real Time CGM vs POC) single center RCT at the Baltimore VA Medical Center. One hundred and twenty individuals will be recruited and randomly assigned (1:1) to either Real Time CGM or to POC following hospital discharge. All subjects will be followed from for 3 months post hospital discharge.

详细描述

Utilizing CGM devices for patients with diabetes at hospital discharge can be a feasible and easily to implement intervention, improving glycemic control. Compared to Point of Care (POC) glucose testing, CGM devices can provide an easier and painless method for monitoring blood glucose levels. By checking glucose values every couple of minutes, having alarm features and by having the ability to provide remote glucose monitoring (with software applications -smartphones-Bluetooth and internet), CGMs can have many benefits for patients with diabetes following hospital discharge: They can help patients with diabetes and their providers to achieve better glucose control after hospital discharge, reducing hyperglycemia, hypoglycemia and glucose variability, conditions that are associated with adverse outcomes among patients with diabetes. As extreme glucose values (hyperglycemia -hypoglycemia- glucose variability) are more common during illness in patients with diabetes, frequent glucose monitoring by CGMs can help patients as also medical providers to utilize them as another "vital sign", leading to early interventions.

These early interventions can have many other potential beneficial health effects. By monitoring glucose values closely, they can decrease hyperglycemia and hypoglycemia leading to better glucose control, reduced post discharge complications and as a result decrease readmission rates and mortality. Hospital readmissions, especially when they occur during the early period after hospital discharge, represent a marker of poor-quality healthcare delivery and have been associated with increased health care costs. In an effort to reduce readmission rates, the Centers for Medicare and Medicaid Services (CMS) Readmissions Reduction Program penalizes hospitals with high 30-day readmission rates. Among patients, those with diabetes have high readmission rates, ranging between 14% and 26%. This is translated to increased hospital expenses: It has been estimated that the cost of 30-day readmissions for patients with diabetes is nearly $25 billion. In addition, using CGM devices early upon discharge can lead to decreasing Emergency Department (ED) visits and post discharge mortality.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥18 years of age
  • Patients with diabetes who are anticipated to be treated with any type of insulin after hospital discharge and with or without non-insulin medications (excluding those who are expected to be treated with correctional-sliding scale insulin regimens only
  • Uncontrolled glycemic control, defined as hyperglycemia with HbA1c ≥8%

排除标准

  • Patients with diabetes who are anticipated to be treated with diet only, any combination of non-insulin antidiabetic drugs only, sliding scale correctional insulins (with or without non-insulin medications) after hospital discharge.
  • Patients at the time of screening on insulin pumps or CGMs
  • Pregnant patients
  • Patients with extensive skin disease or allergies that preclude wearing the CGM sensor
  • Patients without current access of (or who are unable to obtain) a smartphone device and internet
  • Patients who have end-stage renal disease requiring dialysis
  • Patients with significant psychiatric illness or any other condition which by investigator decision makes the subject incapable of understanding the objectives and potential consequences of the study
  • taking hydroxyurea
  • Employed by, or having immediate family members employed by Dexcom, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial

结局指标

主要结局

Change in glycemic control

时间窗: 90 days

HbA1c

Change in hypoglycemia events

时间窗: 90 days

Hypoglycemia \< 70 mg/dL

Change in Glucose Variability

时间窗: 90 days

Glucose Variability- Coefficient of Variation (CV%)

Change in Time In Range (TIR)

时间窗: 90 days

Change TIR (70-180 mg/dL)

Change in Glycemic Risk Index (GRI)

时间窗: 90 days

GRI (Hyperglycemia Component/Hypoglycemia Component)

Change in average glucose values at 90 days post discharge.

时间窗: 90 days

Change in Average glucose values (mg/dL)

次要结局

  • Change in 30-day readmission rates(30 days)
  • Change in 60-day readmission rates(60 days)
  • Change in 90-day readmission rates(90 days)
  • Change in Emergency Department (ED) visits at 30-days(30 days)
  • Change in ED visits at 60 days(60 days)
  • Change in ED visits at 90 days(90 days)
  • Change in Mortality rates at 30 days(30 days)
  • Change in mortality rates at 60 days(60 days)
  • Change in mortality rates at 90 days(90 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验